Genetic Engineering & Biotechnology News

AUG 2017

Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D community with critical information on the tools, technologies, and trends that drive the biotech industry.

Issue link: http://gen.epubxp.com/i/850756

Contents of this Issue

Navigation

Page 27 of 37

26 | AUGUST 2017 | GENengnews.com | Genetic Engineering & Biotechnology News Application Note E ngagement of intracellular targets is often critical to drug mechanisms . Es- tablishing a target engagement (TE) profile is an important step in small- molecule drug discovery as well as chemical probe development. 1 TE involves monitor- ing the binding between protein targets and small molecules inside live cells. In drug dis- covery, TE plays a central role as it enables one to determine mode of action and then to correlate to functional efficacy. 2 Ideal TE methods should possess the ability to 1) quantitate target occupancy or binding between the target protein and the small molecule in live cells, rather than ly- sates; 2) determine the selectivity of the small molecule for other closely related proteins in live cells; and 3) measure the direct or proximal binding between target and small molecule in live cells, rather than monitor a distal event that can be affected by multiple pathways. 1 There are several methods to measure TE in live cells, including but not limited to affinity-based chemoproteomics, cellular thermal shift assays (CETSAs), and enzyme fragment complementation-based ligand stabilization. 2 Most of these techniques fail to meet the qualities of an ideal TE assay as described above. Live-Cell Quantitative Target Engagement Assay for Drug Discovery Here we describe an ideal method, the NanoBRET™ Target Engagement Assay, which is a quantitative, direct-binding tech- nology capable of integrating compound selectivity across closely related family mem- bers. The assay is applicable to many target classes and is scalable for multiwell formats. Using bioluminescence resonance energy transfer (BRET), we developed the first quantitative T E method capable of mea- suring compound binding to selected target proteins in live cells without disrupting the cell membrane. Four key components of the assay include: 1) cellular-expressed target protein fused to the very bright NanoLuc ® luciferase; 2) cell-permeable fluorescent tracer that reversibly binds to target protein; 3) substrate for NanoLuc luciferase; and 4) Extracellular NanoLuc Inhibitor to ensure signal originates from live cells. Figure 1A shows a schematic of the competitive bind- ing assay. Representative competitive bind- ing data for HDAC1 and BRD4 expressed in live cells are shown in Figures 1B & 1C, respectively. NanoBRET TE assays work with full- length, wild-type, truncated, or point mu- tant target proteins to better understand compound mechanism of action. Waring et al. 3 used full-length BRD4 as well as trun- cated and point mutant variants to decipher a BiBET ligand that displays highest affinity when both domains of BRD4 are engaged simultaneously (Figure 1C). We developed broad- coverage cell-per- meable NanoBRET fluorescent tracers and NanoLuc-target fusion DNA constructs for assessing selectivity across closely related tar- get proteins, such as the HDAC class I and IIb family members (Figure 1D) and BET Bromo- domain family. These assays are commercially available. Newer NanoBRET TE Assays for new target classes are in development, which may, along with NanoLuc-target fusion DNA constructs, be sourced through Promega's Custom Assay Services. Residence-Time Analysis in Live Cells Residence time is the lifetime that a ligand remains bound to its target protein under nonequilibrium, open conditions. 4 Drugs are designed to be used in living systems where they are subject to nonequilibrium condi- tions associated with absorption, distribu- tion, metabolism, excretion, etc. Therefore, residence-time analysis is an important pa- rameter to modulate drug candidate efficacy and toxicity. Fast binding of tracers and long-signal half-life of NanoLuc enable live-cell resi- dence- time analysis (Figure 2A). The faster a compound dissociates from its target, the sooner the tracer can bind, resulting in an increase in BRET signal as a function of time. Representative NanoBRET residence- time analyses for several compounds against HDAC1 (Figure 2B) or BRD4 (Figure 2C) were published by Robers et al. 5 and Waring et al., 3 respectively. The technique may also be used to better understand mechanisms of action. For ex- ample, the approved drug FK228 (Romidep- sin) shows prolonged effects at inhibiting HDAC activity in cells. We used NanoBRET to determine whether this action is due to long residence time. 5 FK228 had the high- est affinity of the compounds tested against HDAC1 (Figure 1B) as well as very long resi- dence time (Figure 2B). Summary The NanoBRET TE method allows direct quantitative measurement of compound af- finity for a target protein under physiological conditions, measurement of compound se- lectivity against closely related target protein family members, and a real-time assessment of compound residence time all in live cells. Because NanoLuc is so bright, target protein- NanoLuc fusions do not need to be expressed at high levels. Data shown here were conduct- ed in 96-well assay plates, and the assays are scalable to 384-well or higher density, making it suitable for chemical probe development and multiple phases of drug discovery. n References 1. Simon GM, et al. Nat. Chem. Biol. 9:200 (2013), Determining Target Engagement in Living Systems. 2. Schurmann M, et al. Cell Chem. Biol. 23:435 (2016), Small-Molecule Target Engagement in Cells. DOI: 10.1016/j.chembiol.2016.03.008. 3. Waring MJ, et al. Nat. Chem. Biol. 12:1097 (2016), Potent and Selective Bivalent Inhibitors of BET Bromodomains. DOI: 10.1038/nchembio.2210. 4. Copeland RA. Nat. Rev. Drug Disc. (2016), The drug-target residence time model: a 10-year retrospective. DOI: 10.1038/nrd.2015.18. 5. Robers MB, et al. Nat. Comm. (2015) Target engagement and drug residence time can be observed in living cells with BRET. DOI: 10.1038/ncomms10091. Promega Kristin Huwiler Global Strategic Manager kristin.huwiler@promega.com www.promega.com Do More with a Quantitative Live-Cell Target Engagement Assay NanoBRET Target Engagement Assays Kristin Huwiler, James Vasta, Cesear Corona, Chad Zimprich, Jennifer Wilkinson, and Matthew Robers Figure 1. Schematic of NanoBRET TE equilibrium binding and representative competitive bind - ing data for HDAC and BRD target classes. To determine quantitative target engagement via competition, compounds are added to cells with the fluorescent tracer. Any compound that is cell permeable and binds the target protein will compete with the tracer and result in a decrease in BRET signal. One day prior to compound addition, cells are transiently transfected with the target-NanoLuc fusion DNA construct. Representative BRET measurements of competitive binding data for HDAC1 (1B) and BRD4 (1C) expressed in live HELA and HEK293 cells, respectively. Figure 1A. Schematic of assay for equilibrium analysis. Figure 1B. Titration of competitive ligands for HDAC1. 5 Figure 1C. Titration of competitive ligands for BRD4; BiBET = compound 6, i-BET762 = compound 1. 3 Figure 1D. Concentration-dependent attenua tion of BRET from intracellular HDAC fusions with titration of SAHA in the presence of 1 μM SAHA-NCT tracer. 5 Figure 2. Schematic of NanoBRET TE residence time for HDAC and BRD target classes. Residence- t i m e a n a l ys i s u s i n g N a n o B R E T T E a s s ay i s performed by incubating test compounds with the cells expressing the target-NanoLuc fusion protein, followed by removal of excess com- pound, addition of tracer and substrate, and recording of BRET data kinetically (2A). Figure 2A. Schematic of assay for residence time. Figure 2B. Representative HDAC1 residence time data. 5 Figure 2C. Representative BRD4 residence time data. 3 Advertorial

Articles in this issue

Links on this page

Archives of this issue

view archives of Genetic Engineering & Biotechnology News - AUG 2017